Klaus Schmierer, MB BS, PhD, FRCP, defines the pathophysiology of multiple sclerosis (MS).
Management of Multiple Sclerosis in the Era of COVID-19 Pandemic
Dr Schmierer introduces the disease-modifying therapies (DMT) that are available for patients with MS and their impact on the immune system.
Dr Schmierer explains how the SARS-CoV-2 infection and COVID-19 pandemic have impacted treating patients with MS with DMTs.
An expert delves into the different types of immune responses a patient with MS can have to COVID-19 vaccines if they are also on DMTs.
Dr Schmierer discusses the general guideline vaccination recommendations for patients with MS.
Klaus Schmierer, MB BS, PhD, FRCP, concludes with advice for community physicians and neurologists who are managing patients with MS and COVID-19 or vaccinations.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity
2
Optimizing Speech and Movement Therapy to Improve Motor and Nonmotor Symptoms of Parkinson Disease: Cynthia Fox, PhD, CCC-SLP
3
Insights Into the Neurobiology of Stuttering From 2025 STARS Conference: Shahriar SheikhBahaei, PhD
4
Daridorexant Provides Relief for Insomnia in Women During Menopausal Transition
5
